Vaxcyte, Inc. (PCVX)

NASDAQ

$44.34

-$0.16 (0.36%)

Today

No price data available for this timeframe.

Key Statistics

Day Range

$43.34$44.77

Open $44.59

52 Week Range

$27.66$93.77

Previous Close $44.50

Market Cap5.80B

Volume1.06M

Avg Volume1.71M

P/E (TTM)-9.19

EPS (TTM)$-4.83

Dividend / YieldN/A

Dividend StreakN/A

Latest News for Vaxcyte, Inc.

DEC8

Vaxcyte Doses First Participants in the OPUS Phase 3, Noninferiority Trial Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

Trial Design Finalized in Consultation and Alignment with U.S. Food and Drug Administration Study Designed to Establish a New Standard for Adult Pneumococcal Conjugate Vaccines Through Head-to-Head S...

globenewswire.com•8 days ago

DEC6

Edgestream Partners L.P. Takes $1.61 Million Position in Vaxcyte, Inc. $PCVX

Edgestream Partners L.P. purchased a new position in shares of Vaxcyte, Inc. (NASDAQ: PCVX) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor ...

defenseworld.net•10 days ago

NOV25

8,754 Shares in Vaxcyte, Inc. $PCVX Purchased by AXQ Capital LP

AXQ Capital LP acquired a new position in shares of Vaxcyte, Inc. (NASDAQ: PCVX) during the undefined quarter, according to its most recent 13F filing with the SEC. The fund acquired 8,754 shares of t...

defenseworld.net•21 days ago

NOV16

Bank of Montreal Can Buys 1,274 Shares of Vaxcyte, Inc. $PCVX

Bank of Montreal Can boosted its stake in Vaxcyte, Inc. (NASDAQ: PCVX) by 4.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fir...

defenseworld.net•30 days ago

NOV4

Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study

Final Data from VAX-24 Infant Phase 2 Dose-Finding Study Consistent with Previously Reported Positive Interim Data; Provide Additional Evidence Supporting Higher VAX-31 Doses Being Evaluated in Ongoin...

globenewswire.com•41 days ago

SEP30

Vaxcyte to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in Manufacturing and Services

New Agreement with Thermo Fisher Scientific Expands Domestic Capacity to Support Future Commercial Manufacturing of Vaxcyte's Broad-Spectrum Pneumococcal Conjugate Vaccine Candidates...

globenewswire.com•77 days ago